WHO backs AstraZeneca coronavirus vaccine and plays down risks - Al Jazeera English | Canada News Media
Connect with us

Business

WHO backs AstraZeneca coronavirus vaccine and plays down risks – Al Jazeera English

Published

 on


The UN health agency says there is no causal link between the AstraZeneca vaccine and blood clots and is reviewing data.

The World Health Organization (WHO) has backed the use of the AstraZeneca vaccine after some European countries paused their rollouts following reports of the formation of blood clots in several recipients.

“More than 335 million doses of COVID-19 vaccines have been administered globally so far, and no deaths have been found to have been caused by COVID-19 vaccines,” WHO Director-General Tedros Adhanom Ghebreyesus said on Friday during an online news briefing.

At least five European countries, including Denmark, Norway and Iceland, have suspended the use of a specific batch of the AstraZeneca vaccine after a Danish woman died due to the formation of blood clots after inoculation. Italy’s drug regulator said it halted the use of a separate batch after two people died.

However, the European Medicine Agency stressed that the jabs’ benefits still outweighed their risks and the WHO’s chief scientist Soumya Swaminathan said on Friday that no causal link had been established between the vaccine and clotting.

“As of now we are confident that we should go ahead,” she said, referring to the use of the AstraZeneca jab.

The WHO also said a panel of experts was investigating the latest reports and said any changes to its current recommendations will be communicated immediately to the public.

[embedded content]

Thailand and the Republic of the Congo were the first non-European countries to pause the distribution of the shot on Friday.

Congo received 1.7 million AstraZeneca doses via the global COVAX vaccine-sharing programme on March 2, but is yet to start its inoculation campaign.

WHO’s Assistant Director-General Mariangela Simao said the AstraZeneca batches now under scrutiny were manufactured in Europe, while the drugmaker’s vaccines destined to COVAX were being produced by manufacturers in India and South Korea.

J&J jab granted emergency approval

Separately on Friday, the WHO granted an emergency use listing for the vaccine made by Johnson & Johnson, meaning the one-dose shot can now theoretically be used as part of the international COVAX effort to distribute vaccines globally, including to poor countries without any supplies.

The emergency use listing comes a day after the European Medicines Agency recommended the shot be given the green light across the 27-country European Union.

A massive study that spanned three continents found the J&J vaccine was 85 percent effective in protecting against severe illness, hospitalisations and death. That protection remained strong even in countries like South Africa where new coronavirus variants have been identified that appear to be less susceptible to other licensed vaccines, including the one made by AstraZeneca.

COVAX previously announced it had an initial agreement with J&J to provide 500 million doses, but that is not legally binding.

“We’re hoping by at least July that we have access to doses that we can be rolling out, if not even earlier,” Bruce Aylward, a senior adviser to the WHO chief, said on Friday.

He added that officials were particularly keen to get J&J doses to countries because it requires only one dose and can be stored at regular refrigerator temperatures.

J&J has faced production delays in the US and Europe but has recently signed agreements with rival pharmaceuticals who will help make their vaccine.

In February, Sanofi Pasteur said it would be able to make about 12 million doses of the J&J vaccine at one of its French production sites once the shot is cleared by the EMA. It is aiming to make one billion doses this year.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version